A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics
- 1 September 2019
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 201, 25-38
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 134 references indexed in Scilit:
- Buyer beware? Does the information provided with herbal products available over the counter enable safe use?BMC Medicine, 2011
- Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metaboliteBritish Journal of Clinical Pharmacology, 2009
- Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposureDrug and Alcohol Dependence, 2009
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic CannabinoidsDrug Metabolism and Disposition, 2009
- Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patientsBritish Journal of Clinical Pharmacology, 2008
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoidsBritish Journal of Pharmacology, 2007
- Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differencesBritish Journal of Pharmacology, 2007
- Human Cannabinoid PharmacokineticsChemistry & Biodiversity, 2007
- Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV‐infected patientsBritish Journal of Clinical Pharmacology, 2007